Form 4 for CTSO Cytosorbents Corp
Accepted 2026-09-16 16:05:14 ET · period of report 2026-09-15 · accession 0001104659-26-108246 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-09-16 16:05 | 2026-09-15 | CTSO | Sobel Alan D. | Dir | P - Purchase | $6.10 | +2,500 | 9,887 | +34% | +$15.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | P | A | 1,900 | $6.12 | 9,287 | D | — | — | (F1) These transactions reported on this Form 4 reflect open market purchases made by the Reporting Person. (F2) Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of CytoSorbents Corporation (the "Issuer"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 165 RSUs granted on March 15, 2018, (b) 300 RSUs granted on February 24, 2017, (c) 250 RSUs granted on June 7, 2016, and (d) 2,750 RSUs granted on April 8, 2015 and (ii) 6,422 shares of Common Stock owned directly by the Reporting Person. (F3) Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026. |
| 2 | Common | Common Stock | 2026-09-15 | P | A | 500 | $6.05 | 9,787 | D | — | — | (F1) These transactions reported on this Form 4 reflect open market purchases made by the Reporting Person. (F2) Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of CytoSorbents Corporation (the "Issuer"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 165 RSUs granted on March 15, 2018, (b) 300 RSUs granted on February 24, 2017, (c) 250 RSUs granted on June 7, 2016, and (d) 2,750 RSUs granted on April 8, 2015 and (ii) 6,422 shares of Common Stock owned directly by the Reporting Person. (F3) Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026. |
| 3 | Common | Common Stock | 2026-09-15 | P | A | 100 | $6.01 | 9,887 | D | — | — | (F1) These transactions reported on this Form 4 reflect open market purchases made by the Reporting Person. (F2) Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of CytoSorbents Corporation (the "Issuer"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 165 RSUs granted on March 15, 2018, (b) 300 RSUs granted on February 24, 2017, (c) 250 RSUs granted on June 7, 2016, and (d) 2,750 RSUs granted on April 8, 2015 and (ii) 6,422 shares of Common Stock owned directly by the Reporting Person. (F3) Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026. |